Fujifilm AD candidate fails in Phase II study
Fujifilm Holdings Corp. (Tokyo:4901) said T-817MA failed to significantly improve cognition or global clinical function vs. placebo in a Phase II study to treat mild to moderate Alzheimer's disease, missing the trial's primary endpoints. The small molecule neuroprotective agent was discovered by Fujifilm subsidiary Toyama Chemical Co. Ltd.
Fujifilm said exploratory analyses appeared to show that a low dose of the candidate affected hippocampal volumes. Fujifilm spokesperson Kana Matsumoto said that among patients diagnosed with AD for less than 2.6 years before the start of the study, a 448 mg dose of T-817MA significantly delayed the advancement of cognitive decline vs. placebo. The high dose also significantly reduced biomarker phosphorylated tau (p-tau) 231 vs. placebo. ...